Tue, Sep 16, 2014, 2:01 AM EDT - U.S. Markets open in 7 hrs 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Aradigm Corporation Message Board

  • CJL72 CJL72 Dec 21, 2010 4:22 PM Flag

    cNOTES:ARDM.OB

    ARDM.OB: Aradigm Corp.

    Company is located in the great State of California;

    Aradigm Corporation: Focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases.
    The Company’s principal activities to date have included conducting research and development and developing collaborations. Management does not anticipate receiving any revenues from the sale of products in the upcoming year, except for royalty revenue from Zogenix, Inc.

    @ 16 Cents:, (0.00), (2.50%), $$MM, Some Rounding;

    Desc, Breakdown, Price: , Metric. , Weight. , Primary Weight Adj Trading Metric. ,Year, Weight Adj Price.

    20.Net Income or Loss: , PTInc.St. 0.16 , (9.13) , 1.82 , (16.6) ,2010, 0.29
    21.Std Value , PtStdVal/Rev:, 0.16 , 0.02 , 1.44 , 0.03 ,2010, 0.23
    22.Balance Sheet: , PTNetBSFlexFactor: 0.16 , 2.04 , 1.19 , 2.43 ,2010, 0.19
    23.Discretionary Cash Per CF: , PT Discret. CashApprox($3.5M): 0.16 , 5.96 , 0.75 , 4.48 ,2010 0.12
    24.Ownership Equity Metric: , PT OE : 0.16 , (0.28) (0.63) 0.17 ,Low 2010, (0.10)

    Sum Trading At: ,Metric, (1.38_6) ,Weight, 4.6_7 ,Primary Weight Adj Trade Metric, (1.46_8) , (0.05) off adjusted level price of 21.3 cents.

    Net$$M: (3.02)
    MinRetGrowth: 0.10
    MinRetInv: 0.12
    Wacc; 0.51_6_7
    Estimated Local Continuing Value in $$M / (0.97)
    Estimated Factor NotLocal in $$M: (9.13_’00_’06_12)
    Estimated ContinuingValueNotLocal in $$M / Potential RoyaltyRev: 8.9
    EstNotLocalprice on Fwd Value: 0.012_398
    0.05, Factor Forward.
    0.24, Price To.

    CF,NTA,REV,Equity: Adjusted, $16.462M, 0.0954/ Per Share,

    CF,NTA, Rev, Equity Further Adj to Value: $$M 19.96, 0.12 Per Share.

    The Desired Low Market Cap Price 4.7M:,

    6:, 0.02715

    Potential Price:,

    7:, 0.01235, (0.014802) , Desired Spread & Spread %, (55%)

    Price to Sched Amts @, 0.012348

    8:, 0.10_67

    Sales Forward:, 8.9

    9:, 8.9, 0.05 ,Per Share & Fwd PriceTo, 0.24

    Adjustments:10:, +3.5 $$M , Per Share:, 0.0203

    11:. BidPriceTo:, 7.45

    12:Market Cap Over / Under Minimum per Bid:, 21.36M, 0.1239 , Per Share: BidPriceTo, 1.22

    13:, Share Price Drop MiLB, , 0.17, 0.10 , Per Share &: %, (41.136_151%)

    14:, Equity:Common, Auth:200M Shares Auth. Per Avg Shares O/S 0.172462, 0.001 $$M,Value, PriceTo:, 27.4

    15:,Primary Co Metric, 390 ; Weighted Adjusted Price; 0.00678 ;Weighted Adjusted Trade Metric; 2.23

    16:, ,Per Desired Spread : MMC Price & Weighted Price, ,+Trading @ Plus, 0.0203_74 ,-Minus, (2.12_80)

    [112.17 @ the Current Bid of.]:, 0.15 ,+Trading @ Premium to MMC, 0.1239 ,+Plus, 455%, Price to Sales 6.5x[Yikes!!!]

    Profile and Website:
    http://au.finance.yahoo.com/q/pr?s=ARDM.OB+Profile

    Disclosure:[x]Own Shares.

    Adjustments:
    Additional Paid in Capital Less DeficitReversed: (7)M, (0.04)
    Balance SheetN/A: (9)M, (0.05)
    Minimum Market Cap : 4.7M, 0.03
    Expense as Cash Activity: 15M, 0.09

    Subtotal:+3.5M, +.0203 / Share

    Recent News:
    SUMAVEL DosePro is Granted First European Approval

    Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program

    Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Detailed Quote for GENTA Inc. NEW (GNTA.OB)

      $ 0.058, -0.009, (-13.43%), Volume: 3.31m

      After Hours: $ 0.058, 0.00, (0.00%), Volume: 5 k

      Current Market Cap approx 130K; @ 5.75 Cents; The most recent SPLIT; 1 for 50;
      Per Quote @ OTCBB.COM;

      Per Most Recent Cash Flow Statement:

      Desc, Breakdown, Price: , Metric. , Weight. , Primary Weight Adj Trading Metric ,Year, Weight Adj Price.

      20. Net Inc / Loss , PT MRQ: 0.0575 , (0.00095) , 382.6 , (0.37), Price1, 22

      21.OperBalanceSheet , PT MRQ: 0.0575 , 0.0423 , 37.4 , 1.58, Price2, 2.15

      22. Investing Cash , PT MRQ: 0.0575 , (1.873) , 2.78 , (5.21), Price3, 0.16

      23. Finance Cash , PT MRQ: 0.0575 , 0.0061 , 2.61 , 0.02, Price4, 0.15

      24. Non Cash Adj , PT MRQ: 0.0575 , 0.0011 , (0.87) , (0.0009) , Price5, (0.05)

      Sum Trading At: ,Primary Metric(s) per CF, (1.82_49) ,Weighted per Price Range / Change, 424.52 ,Primary Weight Adj Trade Metric, (3.98) , (4.84_45) off adjusted level price of 4.9020;

      Bottom Line Cash / Current Assets Change Since ’96: Approx +7.4M;

      Sum Trading At: ,Primary Metric(s) per CF, 0.01674 ,Weighted per Price Range / Change, 426.3 ,Primary Weight Adj Trade Metric, (41) , (4.84_45) off adjusted level price of 4.9020;(10.731M Market Cap) per Current Shares @ 2.220M;


      Net$$M :(-) (133.433)
      Non Cash Adjustments:(+) 120.170
      MinRetGrowth: 0.04
      MinRetInv: 0.04
      Weighted Cost of Capital: 1.002
      Estimated Local Continuing Value in $$M: (3)
      Estimated Factor NOT LOCAL in $$M: 7
      Estimated ContinuingValue:Desired Avg R&D $$M: (19.736,975)
      Est NOT LOCAL Price on LT Fwd Value : 0.1205_404
      (9), Factor Forward.
      (0.0135), Price To.
      0.06% , Desired Percentage Increase in Operating R&D from most recent report.
      Excludes FV Derivative Adjustments;

      Profile:
      http://data.cnbc.com/quotes/GNTAD/tab/4
      Genta Incorporated is a biopharmaceutical company with a diversified product portfolio.

      Reference:[Previous Quarter Posting]
      http://seekingalpha.com/instablog/200555-qualitystocks/87267-genta-inc-getad-ob-reports-second-quarter-2010-corporate-highlights-and-financial-results

      The Late Net Phase Bubble Burst Price, The approximate 200K-300K / Share; hahaha!!!
      [As in, something ridiculous like that,but effective.]

      1 Yr % Change (TTM); (99.98%), 10-Day Avg Volume, 1.7M,
      Large Block Institutional Owners, 7, Total Number of Shares Held 1.2M;
      [Low Turnover]

      Additional Reference that I like to check:
      Per the USDA Website: Select Beef Cuts; Fat Limitations 1-6;
      For the Week Ending Today: per 100 lbs;
      Cut 175, 3 Loin; Strip Loin, 1x1; # of Trades:29, Total Pounds: 321,864;
      Per 40K LB Loads:8.05; Price Range 424.75 to 457.11;
      Weighted Average Price 436.15;

      Do not own shares; New to Database Recently; Follow the Company;

    • Note6. Collaborations and Royalty Agreements: Zogenix

      In August 2006, the Company sold all of its assets related to the Intraject needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a privately-held pharmaceutical company.
      Zogenix is responsible for further development and commercialization efforts of Intraject (now rebranded under the name DosePro).
      Under the terms of the asset sale agreement, the Company received a $4.0 million initial payment from Zogenix and was entitled to a $4.0 million milestone payment upon initial U.S. commercialization, as well as quarterly royalty payments in the amount of 3% of Net Sales of DosePro products.
      In December 2007, Zogenix submitted a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for the migraine drug sumatriptan using the needle-free injector DosePro (“SUMAVEL* DosePro”).
      The NDA was accepted for filing by the FDA in March 2008.
      The same month, Zogenix entered into a license agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH to develop and commercialize SUMAVEL DosePro in the European Union.

 
ARDM
10.08-0.48(-4.55%)Sep 15 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
JDS Uniphase Corporation
NasdaqGSMon, Sep 15, 2014 4:15 PM EDT